MCM7

Across TCGA pan-cancer cohorts, MCM7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MCM7 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MCM7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MCM7 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where MCM7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.230	0.675	.005	23	view →
LSCC	DFS	Tertile	II,III,IV	0.853	0.493	.010	16	view →
LUAD	OS	Tertile	All	0.585	1.000	.002	14	view →
COAD	DFS	Tertile	II,III,IV	0.911	1.000	.032	12	view →
HNSC	OS	Tertile	All	0.787	0.924	.013	5	view →
CCRCC	OS	Tertile	All	0.628	1.000	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MCM7–PDAC (OS)

Open the PDAC breakdown →